SEEL - SEELOS THERAPEUTICS, INC.
IEX Last Trade
1.28
1.078 84.219%
Share volume: 0
Last Updated: Tue 15 Oct 2024 08:13:28 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.82%
PREVIOUS CLOSE
CHG
CHG%
$0.20
0.00
0.00%
Fundamental analysis
44%
Profitability
50%
Dept financing
22%
Liquidity
52%
Performance
42%
Performance
5 Days
0 0%
1 Month
0 0%
3 Months
760.44%
6 Months
347.69%
1 Year
86.54%
2 Year
-86.14%
Key data
Stock price
$1.28
DAY RANGE
$0.20 - $1.46
52 WEEK RANGE
$0.20 - $11.67
52 WEEK CHANGE
$87.74
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Raj Mehra
Region: US
Website: seelostherapeutics.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: seelostherapeutics.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Seelos Therapeutics, Inc. focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the. treatment of acute suicidal ideation and behavior in patients with major depressive disorders.
Recent news